Condensed Consolidated Statement of Operations (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Revenue
Tissue sales	$ 8,523,348	$ 7,670,949
Royalties and other	95,459	99,052
Total Revenue	8,618,807	7,770,001
Cost of tissue and medical devices sales	3,120,686	1,858,722
Gross Profit	5,498,121	5,911,279
Operating Expenses
General and administrative	2,857,082	2,590,772
Sales and marketing	3,798,377	4,146,343
Depreciation and amortization	106,378	119,074
Non-cash consulting expense	(30,297)	328,253
Total Operating Expenses	6,731,540	7,184,442
Loss from Operations	(1,233,419)	(1,273,163)
Other Income (Expense)
Interest expense	(1,063,988)	(170,781)
Change in warrant derivative liability	635,355	217,551
Other income (expense)	(7,206)	179,598
Total Other Income (Expense)	(435,839)	226,368
Net Loss Before (Provision) Benefit for Income Taxes	(1,669,258)	(1,046,795)
(Provision) Benefit for Income Taxes
Current	0	0
Deferred	0	0
Net Loss	$ (1,669,258)	$ (1,046,795)
Net loss per share:
Basic (in dollars per share)	$ (0.04)	$ (0.03)
Dilutive (in dollars per share)	$ (0.04)	$ (0.03)
Shares used in the computation:
Basic (in shares)	42,926,564	41,548,087
Dilutive (in shares)	42,926,564	41,548,087